Protalix BioTherapeutics, Inc

(NYSE MKT:PLX)

Latest On Protalix BioTherapeutics, Inc (PLX):

Date/Time Type Description Signal Details
2023-05-30 18:53 ESTNewsProtalix BioTherapeutics Stock: FDA Approval For Elfabrio To Drive ProfitabilityN/A
2023-05-23 16:25 ESTNewsProtalix stock rises as biotech set to join Russell 3000 IndexN/A
2023-05-18 09:36 ESTNewsProtalix nabs $20M milestone on approval for Fabry disease therapyN/A
2023-05-10 19:27 ESTNewsProtalix surges ~15% after Fabry disease therapy Elfabrio wins FDA approvalN/A
2023-05-08 14:16 ESTNewsProtalix, Chiesi Fabry disease drug PRX-102 gets approval in EUN/A
2023-05-04 15:36 ESTNewsProtalix BioTherapeutics GAAP EPS of -$0.05, revenue of $9.59MN/A
2023-05-04 15:36 ESTNewsProtalix Biotherapeutics, Inc. (PLX) Q1 2023 Earnings Call TranscriptN/A
2023-02-27 18:33 ESTNewsProtalix BioTherapeutics GAAP EPS of -$0.22 beats by $0.17, revenue of $62.89M beats by $17.75MN/A
2023-02-27 18:33 ESTNewsProtalix BioTherapeutics (PLX) Q4 2022 Earnings Call TranscriptN/A
2023-02-26 13:46 ESTNewsProtalix Undervalued On CHMP Recommendation Of PRX-102 For Fabry DiseaseN/A
2023-02-24 21:14 ESTNewsProtalix BioTherapeutics Q4 Earnings PreviewN/A
2023-02-10 03:55 ESTNewsThe Prognosis For Protalix BioTherapeuticsN/A
2022-12-22 02:26 ESTNewsProtalix Biotherapeutics to delist its common stock from Tel Aviv Stock ExchangeN/A
2022-12-06 06:10 ESTNewsFDA accepts Protalix's resubmitted license application for Fabry disease drug PRX-102N/A
2022-11-14 13:34 ESTNewsProtalix BioTherapeutics GAAP EPS of -$0.07, revenue of $14.18MN/A
2022-11-14 13:34 ESTNewsProtalix stock rises on FDA refiling for Fabry disease drug PRX–102N/A
2022-11-14 13:33 ESTNewsProtalix BioTherapeutics, Inc. (PLX) Q3 2022 Earnings Call TranscriptN/A
2022-11-11 15:16 ESTNewsProtalix BioTherapeutics Q3 Earnings PreviewN/A
2022-08-15 20:09 ESTNewsProtalix BioTherapeutics GAAP EPS of -$0.11 beats by $0.07, revenue of $8.75M beats by $6.08MN/A
2022-08-15 20:09 ESTNewsProtalix BioTherapeutics Inc. (PLX) CEO Dror Bashan on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-12 23:41 ESTNewsProtalix BioTherapeutics Q2 Earnings PreviewN/A
2022-05-16 17:30 ESTNewsProtalix BioTherapeutics GAAP EPS of -$0.05, revenue of $16.09MN/A
2022-05-16 17:29 ESTNewsProtalix BioTherapeutics, Inc. (PLX) CEO Dror Bashan on Q1 2022 Results - Earnings Call TranscriptN/A
2022-04-06 19:50 ESTNewsStarted In 2016, Protalix's 2-Year Fabry Head-To-Head Trial Has Crossed The Finish LineN/A
2022-04-04 21:52 ESTNewsProtalix stock soars 33% as PRX–102 for Fabry disease equals Sanofi's Fabrazyme in trialN/A
2022-03-31 15:45 ESTNewsProtalix BioTherapeutics GAAP EPS of -$0.62 misses by $0.03, revenue of $38.35M beats by $0.76MN/A
2022-03-31 15:45 ESTNewsProtalix BioTherapeutics (PLX) CEO, Dror Bashan on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-19 04:20 ESTNewsProtalix, Chiesi report final data from late-stage study of PRX‑102 for Fabry diseaseN/A
2022-03-19 04:19 ESTNewsProtalix: Fabry BRIGHT Trial Data May Not Be So Bright After AllN/A
2022-02-24 17:19 ESTNewsProtalix, Chiesi Global file for EU approval of PRX-102 for Fabry diseaseN/A
2022-01-07 08:56 ESTNewsProtalix Biotherapeutics: Is It Worth The Wait?N/A
2021-11-16 06:10 ESTNewsProtalix BioTherapeutics, Inc. (PLX) CEO Dror Bashan on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-13 02:27 ESTNewsProtalix BioTherapeutics Q3 2021 Earnings PreviewN/A
2021-10-15 19:25 ESTNewsProtalix BioTherapeutics, Inc. (PLX) CEO Dror Bashan On Q2 2021 Results - Earnings Call TranscriptN/A
2021-10-15 19:09 ESTNewsProtalix and Chiesi announce final dosing of last Fabry disease patient in late-stage trialN/A
2021-10-14 23:27 ESTNewsLacking BALANCE, Protalix TumblesN/A
2021-10-11 16:06 ESTNewsProtalix to include two-year data in marketing application for Fabry disease candidateN/A
2021-08-17 19:02 ESTNewsProtalix BioTherapeutics, Inc.'s (PLX) CEO Dror Bashan on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-16 23:06 ESTNewsProtalix BioTherapeutics, Inc. (PLX) CEO Dror Bashan on Q1 2021 Results - Earnings Call TranscriptN/A
2021-08-15 09:07 ESTNewsProtalix BioTherapeutics Q2 2021 Earnings PreviewN/A
2021-08-02 22:04 ESTNewsProtalix Bio submits Type A meeting request to FDA for PRX-102 in Fabry diseaseN/A
2021-07-21 19:44 ESTNewsProtalix Bio tanks 15% on reported adverse events in late-stage PRX-102 study in Fabry diseaseN/A
2021-07-21 19:32 ESTNewsProtalix Beaten Down By Covid Logistics, But Continues To Show Good DataN/A
2021-04-28 20:28 ESTNewsProtalix Bio slides on FDA rejection of experimental therapy for Fabry diseaseN/A
2021-04-28 20:26 ESTNewsProtalix Bio says FDA rejection of PRX–102 was not due to safety/ efficacy issuesN/A
2021-04-01 02:26 ESTNewsProtalix BioTherapeutics, Inc.'s (PLX) CEO Dror Bashan on Q4 2020 Results - Earnings Call TranscriptN/A
2021-03-31 06:35 ESTNewsProtalix BioTherapeutics (PLX) CEO, Dror Bashan on Q4 2020 Results - Earnings Call TranscriptN/A
2021-03-30 11:17 ESTNewsProtalix BioTherapeutics EPS beats by $0.12, beats on revenueN/A
2021-03-30 11:17 ESTNewsProtalix BioTherapeutics stock up after FY revenue beatN/A
2021-02-23 19:16 ESTNewsProtalix Bio up 6% on positive PRX–102 data in Fabry diseaseN/A

About Protalix BioTherapeutics, Inc (PLX):

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; OPRX-106, an orally-delivered protein product candidate for the treatment of inflammatory bowel disease, as well as completed Phase IIa clinical trial for ulcerative colitis patients; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; and PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is headquartered in Karmiel, Israel.

PLX Quotes by TradingView

See Advanced Chart

General

  • Name Protalix BioTherapeutics, Inc
  • Symbol PLX
  • Type Common Stock
  • Exchange NYSE MKT
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 196
  • Last Split Factor1:10
  • Last Split Date2019-12-20
  • Fiscal Year EndDecember
  • IPO Date1998-05-15
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.protalix.com
View More

Valuation

  • Forward PE 161.29
  • Price/Sales (Trailing 12 Mt.) 1.95
  • Enterprise Value Revenue 3.96
  • Enterprise Value EBITDA 60.09
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.02
  • Profit Margin -11%
  • Operating Margin 3%
  • Return on Assets 2%
  • Revenue 61.16 million
  • Earnings Per Share -$0.17
  • Revenue Per Share $2.49
  • Gross Profit 43.8 million
  • Quarterly Earnings Growth -24.3%
View More

Highlights

  • Market Capitalization 228.73 million
  • EBITDA 3.49 million
  • PE Ratio 10.11
  • PEG Ratio -0.1
  • Analyst Target Price $13
  • Book Value Per Share -$0.46
View More

Share Statistics

  • Shares Outstanding 45.38 million
  • Shares Float 21.89 million
  • % Held by Insiders 3284%
  • % Held by Institutions 15.89%
  • Shares Short 1.46 million
  • Shares Short Prior Month 505545
  • Short Ratio 0.97
  • Short % of Float 3%
  • Short % of Shares Outstanding 3%
View More

Technicals

  • Beta 2.83
  • 52 Week High $7.02
  • 52 Week Low $2.11
  • 50 Day Moving Average 4.87
  • 200 Day Moving Average 3.96
View More

Dividends

  • Dividend Date 2019-12-20
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Protalix BioTherapeutics, Inc (PLX) Dividend Calendar:

PLX's last dividend payment was made to shareholders on December 20, 2019.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Protalix BioTherapeutics, Inc (PLX) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-10-29$N/A-$0.14-$0.08-75%
2020-06-302020-08-10$N/A-$0.13-$0.2136.59%
2020-03-312020-06-01$21.65 million$0.10-$0.30133.33%
2019-12-312020-03-12$17.76 million$0.02-$0.25108%
2019-09-302019-11-07$14.25 million-$0.20-$0.3542.86%
2019-06-302019-08-08$12.25 million-$0.50-$0.30-66.67%
2019-03-312019-05-06$10.44 million-$0.50-$0.25-100%
2018-12-312019-03-18$10.35 million$0.70-$0.45255.56%
2018-09-302018-11-07$12.34 million-$1.00-$0.40-150%
2018-06-302018-08-09$7 million-$0.80-$0.40-100%
2018-03-312018-05-09$6.71 million-$0.60-$0.9033.33%
2017-12-312018-03-06$2.47 million-$1.00-$0.60-66.67%
2017-09-302017-11-08$7.53 million-$0.90-$0.45-100%
2017-06-302017-08-09$6.36 million-$0.06$0.65-109.23%
2017-03-312017-05-10$2.89 million-$4.80-$0.90-433.33%
2016-12-312017-03-16$2.08 million-$0.20-$1.1081.82%
2016-09-302016-11-09$4.67 million-$0.70-$1.0030%
2016-06-302016-08-08$1.77 million-$1.10-$0.90-22.22%
2016-03-312016-05-09$679000-$0.90-$0.75-20%
2015-12-312016-03-08$-5349000$0.77$0.6813.24%
2015-09-302015-11-10$1.34 million-$0.04-$0.0850%
2015-06-302015-08-11$4.62 million-$0.05-$0.0837.5%
2015-03-312015-05-07$5.1 million-$0.06-$0.0825%
2014-12-312015-03-12$1.38 million-$0.09-$0.04-125%
2014-09-302014-11-10$3.71 million-$0.09-$0.04-125%
2014-06-302014-08-07$2.69 million-$0.70-$0.700%
2014-03-312014-05-08$7.38 million-$0.80-$0.43-86.05%
2013-12-312014-03-13$1.12 million-$1.20-$0.32-275%
2013-09-302013-11-07$3.36 million-$0.60-$0.8025%
2013-06-302013-08-08$3.06 million-$0.70-$0.50-40%
2013-03-312013-05-09$3.97 million-$0.50-$0.6523.08%
2012-12-312013-02-28$48000-$1.10-$0.70-57.14%
2012-09-302012-11-07$5.39 million-$0.60-$1.2050%
2012-06-302012-08-05$25.26 million$1.00-$0.80225%
2012-03-312012-05-09$3.73 million-$0.70-$0.8012.5%
2011-12-312012-02-27$689000-$1.00-$1.000%
2011-09-302011-11-07$897000-$1.00-$1.1513.04%
2011-06-302011-08-08$-4618000-$1.60-$1.20-33.33%
2011-03-312011-05-04$6 million-$0.60-$0.623.23%
2010-12-312011-02-23$5.78 million-$1.10-$0.62-77.42%
2010-09-302010-11-08$3.18 million-$0.30-$1.0671.7%
2010-06-302010-08-05$1.14 million-$1.20-$0.84-42.86%
2010-03-312010-05-10$1.14 million-$1.00-$1.032.91%
2009-12-312010-02-26$388000-$1.90$1.15-265.22%
2009-09-302009-11-09$N/A-$0.80-$0.70-14.29%
2009-06-302009-08-03$N/A-$0.70-$0.8012.5%
2009-03-312009-05-11$N/A-$0.70-$0.8012.5%
2008-12-312009-03-06$N/A-$0.90-$0.955.26%
2008-09-302008-11-10$N/A-$0.90-$0.70-28.57%
2008-06-302008-09-03$N/A-$0.56
2008-03-312008-05-28$N/A-$0.67
2007-12-312008-03-17$N/A-$0.70-$0.50-40%
2007-09-302007-11-28$N/A-$0.72
2007-06-302007-06-30$N/A-$1.39
2007-03-312007-03-31$N/A-$0.54
2006-12-312006-12-31$N/A-$0.60
2006-09-302006-09-30$N/A-$1.83
2006-06-302006-06-30$N/A$0.50
2006-03-312006-03-31$N/A-$0.19
2005-12-312005-12-31$N/A$10.00
2005-09-302005-09-30$N/A-$1.10
2005-06-302005-06-30$N/A-$0.44
2005-03-312005-03-31$N/A-$0.36
2004-12-312004-12-31$N/A-$1.08
2004-09-302004-09-30$N/A-$1.48
2004-06-302004-06-30$N/A-$2.01
2004-03-312004-03-31$N/A-$0.92
2003-12-312003-12-31$N/A-$1.58
2003-09-302003-09-30$N/A-$1.11
2003-06-302003-06-30$N/A-$1.02
2003-03-312003-03-31$N/A-$1.11
2002-09-302002-09-30$N/A-$1.10
2002-06-302002-06-30$N/A-$1.10
2002-03-312002-03-31$N/A-$1.23
2001-09-302001-09-30$N/A-$1.66
2001-06-302001-06-30$N/A-$1.67
2001-03-312001-03-31$N/A-$4.38

Protalix BioTherapeutics, Inc (PLX) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Protalix BioTherapeutics, Inc (PLX) Chart:

PLX chart by TradingView

Protalix BioTherapeutics, Inc (PLX) News:

Below you will find a list of latest news for Protalix BioTherapeutics, Inc (PLX) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Protalix BioTherapeutics, Inc (PLX) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-05-1710.15CALL0 438135.44TRUE00
2024-05-1720.01CALL0 12750FALSE00
2024-05-1730.03CALL0 1250FALSE00
2024-05-1740.05CALL0 10FALSE00
2024-05-1750.05CALL0 100FALSE00
2024-05-1710.1PUT0 600FALSE00
2024-05-1720.85PUT2 85327.96TRUE0.850
2024-05-1730PUT0 0309.37TRUE00
2024-05-1742.78PUT0 1492.17TRUE00
2024-05-1750PUT0 0538.66TRUE00
2024-06-212.50CALL0 00FALSE00
2024-06-2150CALL0 00FALSE00
2024-06-217.50CALL0 00FALSE00
2024-06-212.50PUT0 0337.74TRUE00
2024-06-2150PUT0 0260.3TRUE00
2024-06-217.50PUT0 0386.67TRUE00
2024-08-160.50CALL0 00TRUE00
2024-08-1610CALL0 00TRUE00
2024-08-161.50.15CALL0 16479.47FALSE00
2024-08-162.50.05CALL0 5820FALSE00
2024-08-1650.05CALL0 70FALSE00
2024-08-167.50CALL0 00FALSE00
2024-08-160.50PUT0 00FALSE00
2024-08-1610PUT0 00FALSE00
2024-08-161.50.5PUT0 11098.01TRUE00
2024-08-162.50PUT0 0138.22TRUE00
2024-08-1650PUT0 0244.91TRUE00
2024-08-167.50PUT0 0284.87TRUE00
2024-11-1510.4CALL0 13449.22TRUE00
2024-11-151.50CALL0 00FALSE00
2024-11-152.50.1CALL0 110FALSE00
2024-11-1550CALL0 00FALSE00
2024-11-157.50CALL0 00FALSE00
2024-11-1510.2PUT0 2598.98FALSE00
2024-11-151.50PUT0 0135.33TRUE00
2024-11-152.50PUT0 0148.49TRUE00
2024-11-1550PUT0 0191.3TRUE00
2024-11-157.50PUT0 0255.94TRUE00

Latest PLX Trades:

Date Shares Price
Jun 13, 2022 7:15 PM EST3$1.08
Jun 13, 2022 7:58 PM EST20$1.085
Jun 13, 2022 7:58 PM EST20$1.085

Protalix BioTherapeutics, Inc (PLX) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-11S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1006281/000110465920072466/0001104659-20-072466-index.htm
2018-12-04UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1006281/000000000018037154/0000000000-18-037154-index.htm
2019-02-14UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1006281/000000000019002296/0000000000-19-002296-index.htm
2019-03-15UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1006281/000000000019004851/0000000000-19-004851-index.htm
2019-04-08UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1006281/000000000019006718/0000000000-19-006718-index.htm
2020-04-22UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1006281/000000000020003470/0000000000-20-003470-index.htm
2020-03-23SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1006281/000090266420001614/0000902664-20-001614-index.htm
2019-10-15DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1006281/000110465919054172/0001104659-19-054172-index.htm
2019-10-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000110465919054507/0001104659-19-054507-index.htm
2019-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000110465919060801/0001104659-19-060801-index.htm
2019-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1006281/000110465919060804/0001104659-19-060804-index.htm
2019-11-12DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1006281/000110465919062654/0001104659-19-062654-index.htm
2019-11-15DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1006281/000110465919064785/0001104659-19-064785-index.htm
2019-11-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000110465919064875/0001104659-19-064875-index.htm
2019-11-26DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1006281/000110465919067679/0001104659-19-067679-index.htm
2019-12-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000110465919070966/0001104659-19-070966-index.htm
2019-12-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000110465919074052/0001104659-19-074052-index.htm
2019-12-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000110465919074602/0001104659-19-074602-index.htm
2020-01-033Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1006281/000110465920000972/0001104659-20-000972-index.htm
2020-01-033Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1006281/000110465920000974/0001104659-20-000974-index.htm
2020-01-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1006281/000110465920005965/0001104659-20-005965-index.htm
2020-01-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1006281/000110465920005967/0001104659-20-005967-index.htm
2020-01-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1006281/000110465920005970/0001104659-20-005970-index.htm
2020-01-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1006281/000110465920005971/0001104659-20-005971-index.htm
2020-01-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1006281/000110465920005972/0001104659-20-005972-index.htm
2020-02-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1006281/000110465920011315/0001104659-20-011315-index.htm
2020-02-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000110465920011603/0001104659-20-011603-index.htm
2020-02-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000110465920013512/0001104659-20-013512-index.htm
2020-03-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000110465920032169/0001104659-20-032169-index.htm
2020-03-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000110465920032178/0001104659-20-032178-index.htm
2020-03-1210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1006281/000110465920032540/0001104659-20-032540-index.htm
2020-03-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000110465920035325/0001104659-20-035325-index.htm
2020-03-25SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1006281/000110465920038290/0001104659-20-038290-index.htm
2020-04-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1006281/000110465920045926/0001104659-20-045926-index.htm
2020-04-15DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1006281/000110465920046926/0001104659-20-046926-index.htm
2020-04-17S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1006281/000110465920048223/0001104659-20-048223-index.htm
2020-04-27CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1006281/000110465920051570/0001104659-20-051570-index.htm
2020-04-29424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1006281/000110465920053547/0001104659-20-053547-index.htm
2020-05-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000110465920059038/0001104659-20-059038-index.htm
2020-05-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000110465920059085/0001104659-20-059085-index.htm
2020-05-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000110465920066624/0001104659-20-066624-index.htm
2020-06-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000110465920067973/0001104659-20-067973-index.htm
2020-06-0110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1006281/000110465920067982/0001104659-20-067982-index.htm
2020-06-0110-Q/AQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1006281/000110465920068485/0001104659-20-068485-index.htm
2020-06-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000110465920070904/0001104659-20-070904-index.htm
2020-06-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1006281/000110465920070906/0001104659-20-070906-index.htm
2020-06-11S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1006281/000110465920072466/0001104659-20-072466-index.htm
2020-07-083Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1006281/000110465920082114/0001104659-20-082114-index.htm
2020-07-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1006281/000110465920082116/0001104659-20-082116-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000110465920092367/0001104659-20-092367-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/0001104659-20-092375-index.htm
2020-08-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000110465920092996/0001104659-20-092996-index.htm
2020-08-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1006281/000110465920094751/0001104659-20-094751-index.htm
2020-08-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1006281/000110465920094753/0001104659-20-094753-index.htm
2020-08-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1006281/000110465920094755/0001104659-20-094755-index.htm
2020-08-144/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1006281/000110465920095623/0001104659-20-095623-index.htm
2020-08-144/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1006281/000110465920095626/0001104659-20-095626-index.htm
2020-09-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000110465920102834/0001104659-20-102834-index.htm
2020-10-01424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1006281/000110465920111156/0001104659-20-111156-index.htm
2020-10-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000110465920111165/0001104659-20-111165-index.htm
2019-02-08SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1006281/000114036119002765/0001140361-19-002765-index.htm
2020-02-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1006281/000114036120002573/0001140361-20-002573-index.htm
2018-02-23PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1006281/000114420418010571/0001144204-18-010571-index.htm
2018-03-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000114420418012946/0001144204-18-012946-index.htm
2018-03-0610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1006281/000114420418013053/0001144204-18-013053-index.htm
2018-03-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000114420418016178/0001144204-18-016178-index.htm
2018-03-23DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1006281/000114420418016715/0001144204-18-016715-index.htm
2018-04-02DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1006281/000114420418018393/0001144204-18-018393-index.htm
2018-04-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000114420418020721/0001144204-18-020721-index.htm
2018-04-18DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1006281/000114420418021154/0001144204-18-021154-index.htm
2018-05-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000114420418026337/0001144204-18-026337-index.htm
2018-05-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1006281/000114420418026625/0001144204-18-026625-index.htm
2018-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000114420418028177/0001144204-18-028177-index.htm
2018-05-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000114420418030793/0001144204-18-030793-index.htm
2018-05-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000114420418031991/0001144204-18-031991-index.htm
2018-06-08S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1006281/000114420418033540/0001144204-18-033540-index.htm
2018-06-083Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1006281/000114420418033545/0001144204-18-033545-index.htm
2018-07-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000114420418039629/0001144204-18-039629-index.htm
2018-08-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000114420418042980/0001144204-18-042980-index.htm
2018-08-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1006281/000114420418043286/0001144204-18-043286-index.htm
2018-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000114420418043714/0001144204-18-043714-index.htm
2018-08-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1006281/000114420418043724/0001144204-18-043724-index.htm
2018-09-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1006281/000114420418049515/0001144204-18-049515-index.htm
2018-09-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1006281/000114420418049517/0001144204-18-049517-index.htm
2018-09-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1006281/000114420418049521/0001144204-18-049521-index.htm
2018-09-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1006281/000114420418049522/0001144204-18-049522-index.htm
2018-09-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1006281/000114420418049524/0001144204-18-049524-index.htm
2018-09-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000114420418050260/0001144204-18-050260-index.htm
2018-10-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000114420418052605/0001144204-18-052605-index.htm
2018-10-05PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1006281/000114420418052765/0001144204-18-052765-index.htm
2018-10-17DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/0001144204-18-054229-index.htm
2018-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000114420418057755/0001144204-18-057755-index.htm
2018-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1006281/000114420418057990/0001144204-18-057990-index.htm
2018-12-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000114420418064451/0001144204-18-064451-index.htm
2018-12-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000114420418064759/0001144204-18-064759-index.htm
2018-12-19DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1006281/000114420418065270/0001144204-18-065270-index.htm
2018-12-27CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1006281/000114420418066309/0001144204-18-066309-index.htm
2019-01-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000114420419000672/0001144204-19-000672-index.htm
2019-01-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000114420419001350/0001144204-19-001350-index.htm
2019-02-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000114420419004918/0001144204-19-004918-index.htm
2019-03-11CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1006281/000114420419013136/0001144204-19-013136-index.htm
2019-03-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000114420419014447/0001144204-19-014447-index.htm
2019-03-1810-Q/AQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1006281/000114420419014450/0001144204-19-014450-index.htm
2019-03-1810-Q/AQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1006281/000114420419014453/0001144204-19-014453-index.htm
2019-03-1810-Q/AQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1006281/000114420419014455/0001144204-19-014455-index.htm
2019-03-1810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1006281/000114420419014464/0001144204-19-014464-index.htm
2019-03-29S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1006281/000114420419016978/0001144204-19-016978-index.htm
2019-04-10CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1006281/000114420419018975/0001144204-19-018975-index.htm
2019-04-12DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1006281/000114420419019545/0001144204-19-019545-index.htm
2019-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000114420419023738/0001144204-19-023738-index.htm
2019-05-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1006281/000114420419023895/0001144204-19-023895-index.htm
2019-05-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000114420419027423/0001144204-19-027423-index.htm
2019-05-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000114420419029036/0001144204-19-029036-index.htm
2019-06-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000114420419029957/0001144204-19-029957-index.htm
2019-06-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000114420419031092/0001144204-19-031092-index.htm
2019-07-023Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1006281/000114420419033653/0001144204-19-033653-index.htm
2019-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1006281/000114420419033654/0001144204-19-033654-index.htm
2019-07-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000114420419035361/0001144204-19-035361-index.htm
2019-07-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000114420419036350/0001144204-19-036350-index.htm
2019-08-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000114420419038367/0001144204-19-038367-index.htm
2019-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1006281/000114420419038552/0001144204-19-038552-index.htm
2019-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000114420419039539/0001144204-19-039539-index.htm
2019-08-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000114420419043024/0001144204-19-043024-index.htm
2019-09-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000114420419045689/0001144204-19-045689-index.htm
2019-09-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1006281/000114420419045805/0001144204-19-045805-index.htm
2019-09-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1006281/000114420419045806/0001144204-19-045806-index.htm
2019-10-04PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1006281/000114420419047387/0001144204-19-047387-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1006281/000121390019002214/0001213900-19-002214-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1006281/000121390019002223/0001213900-19-002223-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1006281/000121390020003571/0001213900-20-003571-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1006281/000121390020003584/0001213900-20-003584-index.htm
2020-03-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1006281/000121390020005790/0001213900-20-005790-index.htm
2020-03-30SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1006281/000121390020007898/0001213900-20-007898-index.htm
2020-10-238-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000155837020011697/0001558370-20-011697-index.htm
2020-10-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1006281/000155837020011970/0001558370-20-011970-index.htm
2020-10-2910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1006281/000155837020011974/0001558370-20-011974-index.htm
2018-03-06DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1006281/000157104918000157/0001571049-18-000157-index.htm
2019-04-12EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1006281/999999999519000696/9999999995-19-000696-index.htm
2020-04-29EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1006281/999999999520000909/9999999995-20-000909-index.htm
2018-04-03CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1006281/999999999718004151/9999999997-18-004151-index.htm
2018-12-04CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1006281/999999999718009272/9999999997-18-009272-index.htm
2019-12-17CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1006281/999999999719007896/9999999997-19-007896-index.htm

Protalix BioTherapeutics, Inc (PLX) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Protalix BioTherapeutics, Inc (PLX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 3284%
Institutional Ownership: 1589%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-08-11Eyal RubinSr. VP and CFOBuy246,146.00246,146.00https://www.sec.gov/Archives/edgar/data/1006281/000110465920094755/0001104659-20-094755-index.htm
2020-08-11Dror BashanPresident and CEOBuy447,927.00447,927.00https://www.sec.gov/Archives/edgar/data/1006281/000110465920094753/0001104659-20-094753-index.htm
2020-04-07Aharon SchwartzDirectorBuy64,000.002.43155,264.0064,000.00https://www.sec.gov/Archives/edgar/data/1006281/000110465920045926/0001104659-20-045926-index.htm